Johnson & Johnson (NYSE:JNJ) Shares Sold by Sweet Financial Partners LLC

Sweet Financial Partners LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,086 shares of the company’s stock after selling 175 shares during the period. Sweet Financial Partners LLC’s holdings in Johnson & Johnson were worth $2,607,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Alaska Permanent Fund Corp raised its stake in Johnson & Johnson by 1.4% during the 1st quarter. Alaska Permanent Fund Corp now owns 159,720 shares of the company’s stock valued at $25,266,000 after acquiring an additional 2,267 shares during the last quarter. Adams Asset Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.2% during the first quarter. Adams Asset Advisors LLC now owns 5,762 shares of the company’s stock worth $911,000 after purchasing an additional 70 shares during the period. Stolper Co grew its position in Johnson & Johnson by 9.8% in the 1st quarter. Stolper Co now owns 32,451 shares of the company’s stock valued at $5,133,000 after buying an additional 2,899 shares during the last quarter. Welch Group LLC increased its stake in Johnson & Johnson by 4.7% in the 1st quarter. Welch Group LLC now owns 326,765 shares of the company’s stock valued at $51,691,000 after buying an additional 14,527 shares during the period. Finally, Richard P Slaughter Associates Inc raised its position in Johnson & Johnson by 0.9% during the 1st quarter. Richard P Slaughter Associates Inc now owns 9,246 shares of the company’s stock worth $1,463,000 after buying an additional 82 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday. TD Cowen cut their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Sanford C. Bernstein raised their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Finally, Citigroup upped their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $164.49 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The business has a fifty day moving average of $162.89 and a 200-day moving average of $154.66. The stock has a market cap of $395.87 billion, a price-to-earnings ratio of 10.25, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.66 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.